88% Cancer Cell Kill Rate Achieved by INOVIQ’s Novel CAR-Exosome Treatment
INOVIQ Limited has announced a breakthrough in its cancer treatment program, with its CAR-exosome therapy killing 88% of triple negative breast and lung cancer cells in laboratory studies. This innovation could pave the way for faster, safer, and more accessible cancer therapies.
- CAR-exosome therapy kills 88% of TNBC and lung cancer cells in vitro
- Uses engineered CAR-NK-EVs produced via proprietary EXO-ACE™ method
- Potential for off-the-shelf treatment offering advantages over CAR-T therapies
- Next step involves animal testing before human clinical trials
- Aims to improve safety, efficacy, and production speed in cancer treatment
A Promising Leap in Cancer Therapeutics
INOVIQ Limited (ASX, IIQ) has unveiled compelling preclinical results for its novel cancer treatment platform, demonstrating that its CAR-exosome therapy eradicated 88% of cells from two notoriously aggressive cancers, triple negative breast cancer (TNBC) and non-small-cell lung cancer (NSCLC). These findings, derived from rigorous laboratory studies, mark a significant milestone for the company’s exosome-based therapeutic program.
How the Therapy Works
The treatment harnesses engineered immune cell particles known as CAR-NK-EVs, which are designed to precisely target and kill cancer cells. INOVIQ’s proprietary EXO-ACE™ technology enables the production and purification of these exosomes, ensuring high quality and extended shelf life. Unlike traditional CAR-T therapies that require customization for each patient, this approach aims to deliver an off-the-shelf product that can be manufactured in advance and administered broadly.
Advantages Over Existing Treatments
INOVIQ’s Chief Scientific Officer, Professor Greg Rice, highlighted the potential benefits of this platform, including faster production times, improved safety profiles, and enhanced efficacy. The off-the-shelf nature of the therapy could significantly reduce costs and logistical challenges associated with current cell therapies, which often involve complex and lengthy manufacturing processes tailored to individual patients.
Next Steps and Market Implications
Following these promising in vitro results, the company plans to advance to animal studies to evaluate the therapy’s performance in living systems. Success in these models will be critical before progressing to human clinical trials. INOVIQ’s Chairman, David Williams, emphasized that these developments bring the company closer to delivering transformative treatments that could reshape cancer care.
Broader Context
INOVIQ operates at the forefront of exosome technology, with a portfolio spanning diagnostics and therapeutics aimed at improving cancer detection and treatment. This breakthrough underscores the growing momentum in biotechnology to develop more targeted, effective, and accessible cancer therapies. However, the path from lab success to clinical reality remains complex, with regulatory hurdles and the need for robust safety data ahead.
Bottom Line?
INOVIQ’s breakthrough sets the stage for a new generation of cancer therapies, but the journey from lab bench to bedside is just beginning.
Questions in the middle?
- How will CAR-exosome therapy perform in animal models and human trials?
- What is the anticipated timeline for clinical trial commencement and regulatory approval?
- How does INOVIQ’s platform compare to competing off-the-shelf cancer therapies in development?
